Chemotherapy and Weight Change
Chemotherapy changes body weight in both directions: adjuvant treatment for breast cancer commonly causes weight gain of two to seven kilograms, while cancers of the upper gut and lung often cause loss of weight and muscle.
Plain English
Patient-Friendly Explanation
Many people expect to lose weight during chemotherapy. In practice, weight gain is at least as common, and it is particularly characteristic of chemotherapy given after breast cancer surgery, where average gains of two to six kilograms are reported over treatment and the following year, with some regimens associated with gains of three to seven kilograms. The reasons are several and they add up. Steroid medicines are often given before each treatment to prevent nausea and allergic reactions, and they increase appetite and cause fluid retention. Fatigue makes people less active, so muscle is lost and fat is gained even when the scale moves only a little. In younger women, chemotherapy can shut down the ovaries and bring on an early menopause, which changes where fat is stored and makes weight gain more likely. Appetite and taste can change, and some people eat more to manage nausea or distress. Weight gain during and after cancer treatment is not a cosmetic issue. It increases the risk of type 2 diabetes, high blood pressure and joint problems, it worsens body image and mood at an already difficult time, and in some studies weight gain after a breast cancer diagnosis is associated with a higher risk of recurrence and poorer survival, although not all studies agree. The opposite problem is just as real. Cancers of the oesophagus, stomach, pancreas, lung, head and neck produce cachexia, the combination of unintended weight loss and loss of muscle that cannot be reversed simply by eating more, and it requires early dietetic and medical support. For patients who gain weight, the most useful measures during treatment are keeping physically active within what the treatment allows, including resistance exercise to protect muscle, eating enough protein, working with a dietitian, and reviewing steroid doses and other medicines that drive appetite. Strict crash diets during chemotherapy are not advisable, because adequate nutrition and muscle preservation matter for tolerating treatment. Once treatment is finished, weight and metabolic health should be addressed deliberately, because this is when the extra weight tends to become permanent.
Medical
Clinical Definition
Weight gain is a well-recognised consequence of adjuvant chemotherapy, particularly in breast cancer, where reported mean gains range from about 2 to 6 kg, with gains of 3-7 kg reported with some regimens and the weight largely gained within the first 12 months of treatment. Data from the ATAC and IBIS trials show that significant weight gain occurs in a subset of patients within the first year of endocrine or adjuvant treatment, with younger age, smoking and mastectomy among baseline predictors of gaining more than 5 kg, and that much of the early gain is subsequently lost over five years. Contributing mechanisms include corticosteroid premedication, reduced physical activity and fatigue, chemotherapy-induced ovarian failure and early menopause with its associated change in fat distribution, altered energy intake and taste, fluid retention, and possibly treatment-related changes in insulin sensitivity and body composition with preferential loss of lean mass. Weight gain after diagnosis has been associated in several cohorts with increased risk of relapse and reduced survival, although results are not uniform. At the other end of the spectrum, tumours of the upper gastrointestinal tract, lung, pancreas and head and neck cause cancer cachexia, defined by involuntary weight loss of more than 5% with reduced muscle mass and systemic inflammation, requiring early nutritional intervention and treatment of the underlying disease. Management of treatment-related weight gain rests on supervised exercise - combined aerobic and resistance training improves fatigue, physical function and body composition during adjuvant therapy - adequate protein intake (approximately 1.0 to 1.5 g/kg per day where renal function permits), dietetic review, minimisation of corticosteroid exposure where clinically possible, and treatment of anaemia, hypothyroidism and depression, which are common after cancer treatment and can mimic or worsen fatigue. Severe energy restriction during active treatment is not recommended. After treatment completion, patients should be screened for weight gain, metabolic syndrome and sarcopenia and offered the same structured weight-management support as any other patient, with attention to cardiotoxic regimens, bone health and the possibility of long-term endocrine effects.
Key Insight
Why It Matters
In a weight clinic, patients who have completed cancer treatment are common, and the years after treatment are when preventable metabolic risk accumulates. It helps to raise the subject directly, because many patients assume weight gain after chemotherapy is unavoidable. The levers that work are exercise - particularly resistance work to rebuild muscle - protein intake, careful review of steroid exposure, and treatment of the fatigue and hormonal changes that come with treatment. Where weight loss rather than gain is the problem, cachexia needs dietetic and specialist support early, not a diet.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
